PRKACA/PRKACB/PRKACG Antibody

What are PRKACA, PRKACB, and PRKACG, and why are they important research targets?

PRKACA, PRKACB, and PRKACG are the catalytic subunits of cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). PRKACA (Cα) represents the main catalytic subunit of PKA, while PRKACB (Cβ) and PRKACG (Cγ) have more specialized functions. In the inactive state, these catalytic subunits form a tetrameric holoenzyme with regulatory subunits. When cAMP binds to the regulatory subunits, the complex dissociates, releasing active catalytic subunits that phosphorylate downstream targets .

These proteins are critical research targets because:

• They mediate fundamental cellular processes including differentiation, proliferation, and apoptosis

• PRKACA mutations are implicated in adrenocortical tumors and Cushing syndrome

• They are key components of cAMP-dependent signaling pathways

• Their dysregulation is associated with various pathologies including cancer and bleeding disorders

PRKACA is widely expressed in many tissues, while PRKACG shows testis-specific expression. Understanding their tissue-specific distribution provides crucial insights into their biological functions .

What are the most effective applications for PRKACA/PRKACB/PRKACG antibodies in research?

Based on published research and antibody validation data, the most effective applications include:

Western blot is the most widely used application for these antibodies, with positive detection reported in multiple cell lines including MCF-7, A549, HT-1080, and PC-3 cells, as well as mouse brain and heart tissues . For immunohistochemistry, antigen retrieval with TE buffer (pH 9.0) or citrate buffer (pH 6.0) is recommended for optimal results .

The choice of application should be guided by research objectives and the specific catalytic subunit of interest. For detecting all three isoforms simultaneously, pan-PKA catalytic antibodies recognizing conserved epitopes are available .

How can I ensure specificity when detecting individual PRKACA, PRKACB, and PRKACG isoforms?

Ensuring isoform specificity requires a careful methodological approach:

• Antibody selection: Choose antibodies raised against unique epitopes specific to each isoform. For example, antibodies targeting the C-terminal region of PRKACA (which differs from PRKACB and PRKACG) can provide isoform specificity .

• Validation controls:

  • Positive controls: Use tissues with known expression patterns (e.g., testis for PRKACG)

  • Negative controls: Employ tissues lacking specific isoform expression

  • Knockout/knockdown validation: Test antibodies in systems where specific isoforms are genetically depleted

• Multiple detection methods: Confirm findings using at least two independent techniques (e.g., Western blot plus immunofluorescence)

• Peptide competition assays: Pre-incubate antibodies with the immunizing peptide to confirm binding specificity

• Analysis of molecular weight: PRKACA has a reported mass of 40.6 kDa, while PRKACG is approximately 40.4 kDa. Observing distinct bands can help confirm isoform-specific detection .

• Phospho-specific detection: For studying activation status, phospho-specific antibodies such as anti-phospho-PKA C (Thr197) can detect the active forms of these kinases .

It is important to note that cross-reactivity between isoforms may still occur due to high sequence homology. When absolute specificity is required, complementary molecular techniques such as RT-PCR or mass spectrometry should be considered to validate antibody-based results .

What is the recommended workflow for optimizing immunohistochemistry with PRKACA/PRKACB/PRKACG antibodies?

Based on published protocols and experimental evidence, the following optimization workflow is recommended:

• Fixation optimization:

  • Test both formalin-fixed paraffin-embedded (FFPE) and frozen sections

  • Evaluate different fixation times (6-24 hours) if preparing new samples

• Antigen retrieval method selection:

  • Primary recommendation: TE buffer pH 9.0 (heat-induced epitope retrieval)

  • Alternative: Citrate buffer pH 6.0

  • Compare microwave, pressure cooker, and water bath methods

• Blocking optimization:

  • Test 5-10% normal serum from the species of secondary antibody

  • Include 0.1-0.3% Triton X-100 for membrane permeabilization

  • Consider dual blocking with serum plus 1% BSA

• Antibody dilution titration:

  • Start with manufacturer's recommended range (typically 1:50-1:500)

  • Prepare a dilution series (e.g., 1:50, 1:100, 1:200, 1:500)

  • Include appropriate controls at each dilution

• Incubation conditions optimization:

  • Compare overnight at 4°C versus 1-2 hours at room temperature

  • Test different diluents (PBS, TBS, commercial antibody diluents)

• Detection system selection:

  • Compare sensitivity of DAB versus AEC chromogens

  • Evaluate biotin-free detection systems to reduce background

• Counterstaining and mounting:

  • Optimize hematoxylin counterstaining time

  • Select appropriate mounting medium based on analysis needs

This systematic approach has proven effective for detecting PRKACA in human adrenocortical tissues and PRKACB in brain samples, where careful optimization was required to distinguish specific staining patterns .

How can I investigate the role of PRKACA mutations in adrenocortical tumorigenesis using antibody-based methods?

Investigating PRKACA mutations in adrenocortical tumorigenesis requires a multi-faceted approach combining antibody-based methods with functional analyses:

• Mutation-specific antibody selection:

  • Employ antibodies that can distinguish between wild-type and mutant PRKACA (especially the common Leu206Arg mutation)

  • If mutation-specific antibodies are unavailable, use general PRKACA antibodies alongside genetic screening

• Immunohistochemical analysis of clinical samples:

  • Compare PRKACA expression in normal adrenal cortex versus cortisol-producing adenomas

  • Quantify differences in staining intensity and subcellular localization

  • Research has shown dramatically increased PRKACA expression in clinically resistant samples compared to pre-treatment samples in some cancer cases

• Phospho-specific substrate detection:

  • Assess PKA activity using antibodies against phosphorylated CREB (at Ser133)

  • Higher staining of phosphorylated CREB has been observed in PRKACA mutant adrenocortical adenomas

• Co-immunoprecipitation to assess protein interactions:

  • Investigate the interaction between mutant PRKACA and regulatory subunits

  • The Leu206Arg mutation has been shown to abolish binding between PRKACA and regulatory subunits

  • Protocol: Immunoprecipitate with anti-FLAG to pull down PRKACA, followed by Western blotting using anti-PRKAR1A antibodies

• Subcellular fractionation and localization analysis:

  • Compare nuclear versus cytoplasmic distribution of wild-type and mutant PRKACA

  • Correlate localization with functional consequences

• Functional validation in cell models:

  • Transfect cells with wild-type or mutant PRKACA constructs

  • Monitor PKA activity using phospho-substrate antibodies

  • Assess cellular phenotypes (proliferation, hormone production)

Research has demonstrated that PRKACA mutations lead to constitutively active PKA, contributing to cortisol-producing adenomas. This methodological approach has been successfully employed to establish PRKACA as a major contributor to adrenocortical tumorigenesis .

What strategies can resolve contradictory results when analyzing PRKACA/PRKACB/PRKACG expression across different experimental platforms?

Contradictory results when analyzing PKA catalytic subunits are not uncommon. The following methodological strategies can help resolve discrepancies:

• Critical evaluation of antibody specificity:

  • Validate antibodies using positive and negative controls

  • Perform peptide competition assays to confirm specificity

  • Compare results from multiple antibodies targeting different epitopes

  • Cross-validate with genetic approaches (siRNA knockdown)

• Standardization of sample preparation:

  • Implement consistent protein extraction methods

  • Compare results from different subcellular fractions

  • Control for post-translational modifications that may affect antibody recognition

• Quantitative validation approaches:

  • Employ absolute quantification using mass spectrometry

  • Use targeted proteomics with isotope-labeled internal standards

  • Research has used calibration peptides with isotopic labels for PRKACA, PRKACB, PRKACG to determine absolute quantities

• Cross-platform validation:

  • Compare protein expression (Western blot/IHC) with mRNA expression (RT-PCR/RNA-seq)

  • Evaluate activity (kinase assays) alongside expression data

  • When examining fusion genes like DNAJB1::PRKACA, confirm with both protein and transcript analysis

• Context-dependent expression analysis:

  • Consider tissue-specific expression patterns (e.g., PRKACG is testis-specific)

  • Account for developmental or disease-state variations

  • Analyze expression in appropriate physiological context

• Statistical approaches for resolving contradictions:

  • Meta-analysis of multiple datasets

  • Outlier detection and elimination

  • Calculation of confidence intervals for measurements

When faced with contradictory results, it's important to note that different studies have shown variable findings regarding phosphorylation levels of CREB in PRKACA mutant tissues. For example, Goh et al. demonstrated higher staining of phosphorylated CREB in mutant samples via immunohistochemistry, while Sato et al. found no differences by Western blot . Such discrepancies highlight the importance of employing multiple independent techniques.

What methodological approaches are effective for detecting and characterizing fusion proteins involving PRKACA or PRKACB?

Fusion proteins involving PRKACA or PRKACB (such as DNAJB1::PRKACA in fibrolamellar hepatocellular carcinoma or ATP1B1::PRKACA/B in intraductal oncocytic papillary neoplasms) require specialized detection approaches:

• Antibody selection for fusion protein detection:

  • Use antibodies targeting the PRKACA/B portion of the fusion

  • Employ antibodies against fusion partners (e.g., DNAJB1, ATP1B1)

  • Consider developing custom antibodies against the fusion junction

• RT-PCR based detection:

  • Design primers spanning the fusion breakpoint

  • Use quantitative RT-PCR to measure fusion transcript levels

  • This approach has been successfully used to detect ATP1B1::PRKACA, DNAJB1::PRKACA, and ATP1B1::PRKACB fusion genes

• Western blot considerations:

  • Adjust gel concentration to resolve fusion proteins (which have higher molecular weights)

  • Use gradient gels (4-12%) for optimal separation

  • Include wild-type PRKACA/B controls for size comparison

  • DNAJB1::PRKACA typically shows higher expression than native PRKACA in Western blots

• Immunofluorescence localization:

  • Compare subcellular distribution of fusion versus wild-type proteins

  • Perform co-localization studies with compartment markers

  • Analyze redistribution patterns in affected tissues

• Functional characterization methods:

  • Assess kinase activity using phospho-substrate antibodies

  • Measure cAMP-responsiveness of the fusion protein

  • Evaluate protein-protein interactions via co-immunoprecipitation

• Mass spectrometry approaches:

  • Develop targeted mass spectrometry assays for fusion junctions

  • Use isotopically labeled peptides as internal standards

  • Perform absolute quantification of fusion versus wild-type proteins

Research has demonstrated that fusion proteins involving PRKACA/B are associated with specific pathologies. For example, PRKACA/B fusion genes were detected in 100% (32/32) of typical intraductal oncocytic papillary neoplasms, 46% (13/28) of atypical cases, and 0% (0/20) of controls (P < 0.05) . This differential expression pattern provides diagnostic and research utility.

How should experiments be designed to investigate the relationship between PRKACA/PRKACB/PRKACG expression and disease progression?

Designing experiments to investigate the relationship between PRKACA/PRKACB/PRKACG expression and disease progression requires careful planning:

• Longitudinal sample collection:

  • Compare matched samples from different disease stages

  • Include pre-treatment and post-resistance samples when studying therapy resistance

  • Research has shown increased PRKACA expression in samples after development of clinical resistance to trastuzumab-containing therapy compared to pre-treatment samples

• Quantitative expression analysis:

  • Use validated antibodies for consistent detection

  • Implement digital pathology for objective quantification

  • Perform parallel RNA expression analysis when possible

  • Consider absolute quantification methods for precise comparisons

• Correlation with clinical parameters:

  • Collect comprehensive clinical data (stage, grade, treatment response)

  • Perform statistical analyses to identify significant associations

  • Use multivariate analyses to control for confounding factors

• Functional validation in model systems:

  • Manipulate expression levels in cell lines using overexpression/knockdown

  • Assess phenotypic consequences on proliferation, invasion, and drug response

  • Validate findings in patient-derived xenografts or organoids

• Mechanistic investigation:

  • Analyze downstream signaling pathway activation

  • Investigate interaction with regulatory subunits

  • Assess phosphorylation status of key substrates

• Translational significance assessment:

  • Evaluate potential as biomarkers of disease progression

  • Investigate as therapeutic targets using specific inhibitors

  • Determine predictive value for treatment response

In breast cancer research, high levels of PRKACA expression were found to confer resistance to lapatinib and trastuzumab treatment. Immunohistochemical analysis of patient samples revealed dramatically increased PRKACA expression in clinically resistant samples compared to pre-treatment samples in three of five cases . This methodological approach successfully established PRKACA as a mediator of resistance to HER2-targeted therapy, demonstrating the value of correlating expression with clinical outcomes.

What are the common pitfalls in PRKACA/PRKACB/PRKACG antibody applications and how can they be overcome?

Common pitfalls in PRKACA/PRKACB/PRKACG antibody applications and their solutions include:

When working with phospho-specific antibodies (e.g., phospho-PKA C at Thr197), additional considerations include:

• Phosphatase inhibition:

  • Add phosphatase inhibitors immediately during sample preparation

  • Keep samples cold throughout processing

  • Consider phosphatase treatment controls to validate specificity

• Signal enhancement strategies:

  • Use tyramide signal amplification for low abundance targets

  • Employ polymer-based detection systems for improved sensitivity

  • Consider extended antibody incubation times at lower temperatures

• Protocol optimization for specific applications:

  • For Western blot: Transfer optimization for different molecular weights

  • For IHC: Extended antigen retrieval for formalin-fixed tissues

  • For IF: Careful permeabilization optimization to maintain structure

By addressing these common issues systematically, researchers can significantly improve the reliability and reproducibility of experiments investigating PKA catalytic subunits.

How can I optimize detection of phosphorylated forms of PRKACA/PRKACB/PRKACG in complex biological samples?

Detecting phosphorylated forms of PKA catalytic subunits presents unique challenges. The following optimized methodology addresses these challenges:

• Sample preparation considerations:

  • Harvest cells/tissues rapidly to preserve phosphorylation status

  • Use phosphatase inhibitor cocktails in all buffers (including NaF, Na₃VO₄, and β-glycerophosphate)

  • Maintain samples at 4°C throughout processing

  • Consider phospho-enrichment techniques for low abundance targets

• Antibody selection for phospho-detection:

  • Choose antibodies specifically validated for phospho-epitopes (e.g., phospho-Thr197)

  • Include phospho-specific positive controls

  • Consider using phospho-specific and total protein antibodies in parallel

  • Validate antibody specificity using phosphatase treatment controls

• Western blot optimization:

  • Prefer PVDF membranes for phospho-protein retention

  • Include BSA rather than milk in blocking buffers (milk contains phosphatases)

  • Use 5% BSA in TBS-T for antibody dilution

  • Consider extended overnight incubation at 4°C for primary antibodies

• Immunohistochemistry refinements:

  • Test multiple antigen retrieval methods (EDTA-based buffers often superior)

  • Implement biotin-free detection systems to reduce background

  • Use amplification systems for low abundance phospho-proteins

  • Prepare fresh solutions to maintain phospho-epitope integrity

• Quantification approaches:

  • Normalize phospho-signal to total protein level

  • Use phospho-mimetic and phospho-null controls when available

  • Consider multiplex staining to assess multiple phosphorylation sites

  • Implement digital image analysis for objective quantification

• Advanced techniques for comprehensive analysis:

  • Mass spectrometry for unbiased phosphorylation profiling

  • Phospho-specific flow cytometry for single-cell analysis

  • Proximity ligation assay to detect phospho-dependent interactions

Research demonstrates that phosphorylated forms of type II regulatory subunits can be detected in tumors from PRKACA+/−Prkaca+/− mice using phospho-specific antibodies . These approaches enable investigation of the functional consequences of aberrant PKA signaling in disease contexts.

How can PRKACA/PRKACB/PRKACG antibodies be utilized in studying the role of these kinases in novel disease associations?

Recent research has expanded our understanding of PKA catalytic subunits in disease beyond the well-established roles in endocrine disorders. The following methodological framework enables investigation of novel disease associations:

• Comparative expression profiling:

  • Analyze expression levels across disease versus normal tissues

  • Implement tissue microarray screening for high-throughput analysis

  • Perform subcellular localization studies to detect altered distribution

  • PRKACA is associated with bleeding disorders and PRKACG has been linked to male gonad development disorders

• Mechanistic investigation in disease models:

  • Establish disease-relevant cell models (patient-derived or engineered)

  • Manipulate catalytic subunit expression/activity and assess phenotypic consequences

  • Apply phospho-specific antibodies to track signaling pathway alterations

  • Correlate with functional readouts specific to the disease in question

• Protein-protein interaction analysis:

  • Identify disease-specific binding partners using co-immunoprecipitation

  • Confirm interactions using proximity ligation assays in intact tissues

  • Investigate alterations in PKA holoenzyme composition in disease states

  • Studies have shown that mutations can disrupt interactions between catalytic and regulatory subunits

• Integration with genetic findings:

  • Correlate protein expression/activation with genetic alterations

  • Analyze the impact of disease-associated mutations on protein function

  • Implement CRISPR-based modeling of disease mutations

  • The PRKACG gene has been associated with bleeding disorders (BDPLT19)

• Translational applications:

  • Assess potential as diagnostic or prognostic biomarkers

  • Evaluate as therapeutic targets using specific inhibitors

  • Develop companion diagnostics for PKA-targeting therapies

Novel disease associations currently being investigated include:

• PRKACA in resistance to HER2-targeted therapy in breast cancer

• PRKACA/B fusion genes in intraductal oncocytic papillary neoplasms

• Germline PRKACA amplification causing variable phenotypes

• PKA activity alterations in stromal cells with osteogenic capacity

These methodological approaches facilitate the exploration of PKA catalytic subunits in previously unrecognized disease contexts, expanding our understanding of their biological significance.

What are the methodological considerations for investigating the interactions between PRKACA/PRKACB/PRKACG and their regulatory subunits?

Investigating interactions between PKA catalytic and regulatory subunits requires specialized methodology tailored to the unique characteristics of these protein complexes:

• Co-immunoprecipitation optimization:

  • Use mild lysis conditions to preserve native interactions

  • Consider crosslinking approaches for transient interactions

  • Include appropriate controls (IgG, catalytic subunit alone)

  • Example protocol: Immunoprecipitate with anti-FLAG to pull down PRKACA, followed by Western blotting using anti-PRKAR1A antibodies

• Analysis of PKA holoenzyme composition:

  • DEAE-cellulose chromatography to separate PKA-I and PKA-II

  • Quantify PKA-II to PKA-I ratio in different tissue/disease states

  • Research has shown that PRKACA mutations can alter this ratio

  • Native gel electrophoresis to preserve intact complexes

• cAMP-dependent dissociation analysis:

  • Study kinetics of complex dissociation using purified components

  • Assess impact of mutations on cAMP sensitivity

  • Investigate kinase activity following dissociation

  • cAMP can be used at increasing concentrations (2 μmol/L, 20 μmol/L, and 200 μmol/L) to elute catalytic subunits from regulatory subunits

• Microscopy-based interaction studies:

  • Implement FRET/BRET for real-time interaction analysis

  • Perform proximity ligation assays in fixed cells/tissues

  • Use advanced techniques like FLIM to quantify interaction affinities

  • These approaches have confirmed the absence of interaction between PRKACA variants and regulatory subunits

• Structural analysis considerations:

  • Crystallographic studies of wild-type versus mutant complexes

  • Molecular dynamics simulations to predict interaction changes

  • Structure-guided mutagenesis to validate key interface residues

• Functional consequences assessment:

  • Measure catalytic activity using phospho-substrate antibodies

  • Analyze downstream signaling pathway activation

  • Correlate structural changes with functional outcomes

  • Research shows Leu206Arg PRKACA is constitutively active and not responsive to cAMP stimulation

Recent research has demonstrated that mutations in PRKACA can disrupt interactions with regulatory subunits, leading to constitutive activation and disease. For example, the Leu206Arg mutation abolishes binding between PRKACA and regulatory subunits, which has been confirmed by FRET and co-immunoprecipitation experiments . These methodological approaches provide critical insights into the molecular mechanisms underlying PKA dysfunction in pathological states.